The TruGraf® test is a non-invasive blood test that measures molecular gene expression profiles associated with clinical conditions previously only diagnosed by biopsy in kidney transplant recipients. The results of the TruGraf test provide additional information about the adequacy of immunosuppression and may be used to support decisions in patient management.
This is a single-center, prospective, randomized study to evaluate clinical utility of TruGraf testing in patients with the following characteristics:1.Stable serum creatinine: current serum creatinine \<2.3 mg/dl, \<20% increase compare to the average of the previous 3 serum creatinine levels2.Kidney transplant patients who are:•more than 60 days post-transplant will be included in this study (Study A) •more than 2-yearspost-transplant but less than 5 years post-transplant (\>24 months but \< 60 months) will be included in this study (Study B) Scripps will enroll subjects who are post-transplant and are undergoing routine management. In Study A, patients will receive testing eight times: Month 2 (at time of surveillance biopsy) 6(at time of surveillance biopsy), 9, 12(at time of surveillance biopsy), 15, 18, 21 and 24(at time of surveillance biopsy) (plus or minus two weeks). Results of the genomic analysis will be considered in determining patient treatment plans and as a molecular guide to perform a surveillance biopsy. Clinical data elements using the Scripps EHR and cost of care will be collected for all subjects. In Study B, patients who are at least 2 years post transplant up to 5 years post-transplant will receive testing 8 times: Months 3 ,6, 9, 12, 15, 18, 21 and 24 (plus or minus two weeks)from the time of enrollment into the study. Results of the genomic analysis will be considered in determining patient treatment plans and whether any change is needed, such as whether to perform a surveillance biopsy. Clinical data elements using the Scripps EHR and cost of care will be collected for all subjects. We expect Study A to be completed 24-30months and Study B to be completed in 24-30 months.
Study Type
OBSERVATIONAL
Enrollment
50
5 mL collection PAXgene blood sample
Scripps Clinic
La Jolla, California, United States
Cohort A: Percent or total number of patients who physicians decided could forego a surveillance biopsy due to TruGraf results
Time frame: 12 months post-transplant
Cohort A: Percent or total number of patients who physicians decided could forego a surveillance biopsy due to TruGraf results
Time frame: 24 months post-transplant
Cohort A: Correlation of TruGraf test results with surveillance biopsy
Time frame: 2 years
Cohort A and B: Banff pathology
Banff pathology will be assessed and compared to TruGraf results.
Time frame: 2 years
Cohort A and B: Renal graft function
Renal graft function will be assessed by measuring Estimated Glomerular Filtration Rate (eGFR).
Time frame: 2 years
Cohort A and B: Renal graft function
Renal graft function will be assessed by measuring serum creatinine (sCr) levels.
Time frame: 2 years
Cohort A and B: Cost of patient care
The cost of patient care will be evaluated by measuring the total health care spending for health care services provided during the study period.
Time frame: 2 years
Incidence of death
Time frame: 2 years
Incidence of graft loss
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.